Kim, J.G.; Sandhu, S.K.; Dontula, R.V.; Cooper, J.J.; Sherman, J.; Rochette, M.; Siddiqui, R.; Kim, L.E.; Redell, M.S.; Stevens, A.M.
Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models. Cancers 2025, 17, 1509.
https://doi.org/10.3390/cancers17091509
AMA Style
Kim JG, Sandhu SK, Dontula RV, Cooper JJ, Sherman J, Rochette M, Siddiqui R, Kim LE, Redell MS, Stevens AM.
Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models. Cancers. 2025; 17(9):1509.
https://doi.org/10.3390/cancers17091509
Chicago/Turabian Style
Kim, Julia G., Sohani K. Sandhu, Ritesh V. Dontula, Josh J. Cooper, Jaden Sherman, Max Rochette, Rehan Siddiqui, Lana E. Kim, Michelle S. Redell, and Alexandra M. Stevens.
2025. "Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models" Cancers 17, no. 9: 1509.
https://doi.org/10.3390/cancers17091509
APA Style
Kim, J. G., Sandhu, S. K., Dontula, R. V., Cooper, J. J., Sherman, J., Rochette, M., Siddiqui, R., Kim, L. E., Redell, M. S., & Stevens, A. M.
(2025). Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models. Cancers, 17(9), 1509.
https://doi.org/10.3390/cancers17091509
